University of Birmingham Precision Health Technologies Accelerator
Birmingham's NHS-grade cell and gene therapy facility; received £10m LSIMF grant in April 2026.
Last refreshed: 22 April 2026 · Appears in 1 active topic
Will £10m of LSIMF capital make Birmingham a serious rival to London for cell therapy manufacturing?
Timeline for University of Birmingham Precision Health Technologies Accelerator
Received £10m for cell and gene therapy and mRNA biomanufacturing
UK Startups and Innovation: LSIMF sends £80m+ to four regional sitesWhat is the University of Birmingham Precision Health Technologies Accelerator?
How much did the LSIMF give Birmingham for cell and gene therapy manufacturing?
Why is the UK government funding life sciences manufacturing outside London?
Background
On 14 April 2026, the Life Sciences Innovative Manufacturing Fund (LSIMF) awarded the University of Birmingham Precision Health Technologies Accelerator £10m to expand manufacturing capacity for cell and gene therapy and mRNA products, as part of a four-site, £80m+ geographic-diversification package announced by DSIT.
The Precision Health Technologies Accelerator is the University of Birmingham's specialist translational research and manufacturing facility, designed to take advanced therapy medicinal products (ATMPs) — including cell therapies, viral vectors, and mRNA constructs — from laboratory stage into clinical-grade production. It sits within Birmingham's broader life-sciences cluster, which also encompasses the Queen Elizabeth Hospital Birmingham and the Institute of Cancer and Genomic Sciences.
The £10m award is the LSIMF's explicit policy signal that world-class manufacturing capability need not be concentrated in the Oxford-Cambridge-London Golden Triangle. Birmingham becomes a Midlands anchor for ATMP manufacturing, connecting the university's research output to a GMP-compliant production pathway. With cumulative UK life sciences investment in 2026 reaching £600m, and DSIT targeting £1bn by summer, the Accelerator's grant positions it as a testbed for whether state-backed capex can catalyse private follow-on into regional ATMP infrastructure.